S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Price, News & Analysis

$23.00
-0.39 (-1.67%)
(As of 04/17/2024 ET)
Today's Range
$22.76
$23.54
50-Day Range
$21.66
$25.74
52-Week Range
$20.87
$34.28
Volume
957,822 shs
Average Volume
1.46 million shs
Market Capitalization
$2.38 billion
P/E Ratio
24.21
Dividend Yield
N/A
Price Target
$37.30

Corcept Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.2% Upside
$37.30 Price Target
Short Interest
Bearish
23.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.68mentions of Corcept Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.12 M Sold Last Quarter
Proj. Earnings Growth
43.48%
From $0.92 to $1.32 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.70 out of 5 stars

Medical Sector

54th out of 914 stocks

Pharmaceutical Preparations Industry

20th out of 410 stocks

CORT stock logo

About Corcept Therapeutics Stock (NASDAQ:CORT)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Stock Price History

CORT Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Corcept Therapeutics Incorporated (CORT)
3 Promising Biotech Stocks Driving Weekly Gains
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
CORT May 2024 32.000 call
CORT Apr 2024 31.000 call
CORT Apr 2024 17.000 put
CORT Aug 2024 32.000 put
Top 3 Biotech Stocks to Anchor Your Portfolio
Corcept Therapeutics Inc
Plunge into Profits With These 3 Biotech Stocks
A Checkdown Trade on a Small-Cap Biotech Stock
Corcept Therapeutics: Key Catalysts Ahead
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/17/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
352
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$37.30
High Stock Price Target
$47.50
Low Stock Price Target
$28.00
Potential Upside/Downside
+62.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$106.14 million
Pretax Margin
25.82%

Debt

Sales & Book Value

Annual Sales
$482.38 million
Cash Flow
$0.95 per share
Book Value
$4.92 per share

Miscellaneous

Free Float
84,265,000
Market Cap
$2.37 billion
Optionable
Optionable
Beta
0.48

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

CORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 1-year price targets for Corcept Therapeutics' shares. Their CORT share price targets range from $28.00 to $47.50. On average, they predict the company's stock price to reach $37.30 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2024?

Corcept Therapeutics' stock was trading at $32.48 on January 1st, 2024. Since then, CORT shares have decreased by 29.2% and is now trading at $23.00.
View the best growth stocks for 2024 here
.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 21,330,000 shares, an increase of 5.5% from the March 15th total of 20,220,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is presently 15.0 days. Currently, 23.9% of the shares of the company are sold short.
View Corcept Therapeutics' Short Interest
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Thursday, February, 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.03. The biotechnology company had revenue of $135.41 million for the quarter, compared to analyst estimates of $129.27 million. Corcept Therapeutics had a trailing twelve-month return on equity of 21.98% and a net margin of 21.86%. The company's quarterly revenue was up 31.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.14 earnings per share.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $531.6 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.05%), Los Angeles Capital Management LLC (0.05%), Evanson Asset Management LLC (0.02%), Clearview Wealth Advisors LLC (0.01%), Sound Income Strategies LLC (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CORT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners